Hepatitis  ||| S:0 E:10 ||| NNP
B ||| S:10 E:11 ||| NNP
:  ||| S:11 E:13 ||| :
clinical  ||| S:13 E:22 ||| JJ
application  ||| S:22 E:34 ||| NN
of  ||| S:34 E:37 ||| IN
HBsAg  ||| S:37 E:43 ||| JJ
quantification  ||| S:43 E:58 ||| NN
Since  ||| S:58 E:64 ||| IN
its  ||| S:64 E:68 ||| PRP$
discovery  ||| S:68 E:78 ||| NN
by  ||| S:78 E:81 ||| IN
Blumberg  ||| S:81 E:90 ||| NNP
in  ||| S:90 E:93 ||| IN
1965 ||| S:93 E:97 ||| CD
,  ||| S:97 E:99 ||| ,
hepatitis  ||| S:99 E:109 ||| NNP
B  ||| S:109 E:111 ||| NNP
virus  ||| S:111 E:117 ||| NN
antigen  ||| S:117 E:125 ||| NN
( ||| S:125 E:126 ||| -LRB-
HBsAg ||| S:126 E:131 ||| NNP
)  ||| S:131 E:133 ||| -RRB-
is  ||| S:133 E:136 ||| VBZ
used  ||| S:136 E:141 ||| VBN
as  ||| S:141 E:144 ||| IN
the  ||| S:144 E:148 ||| DT
fingerprint  ||| S:148 E:160 ||| NN
of  ||| S:160 E:163 ||| IN
hepatitis  ||| S:163 E:173 ||| NNP
B  ||| S:173 E:175 ||| NNP
infection ||| S:175 E:184 ||| NN
.  ||| S:184 E:186 ||| .
HBsAg  ||| S:186 E:192 ||| JJ
level  ||| S:192 E:198 ||| NN
reflects  ||| S:198 E:207 ||| VBZ
the  ||| S:207 E:211 ||| DT
transcriptional  ||| S:211 E:227 ||| JJ
activity  ||| S:227 E:236 ||| NN
of  ||| S:236 E:239 ||| IN
the  ||| S:239 E:243 ||| DT
cccDNA ||| S:243 E:249 ||| JJ
.  ||| S:249 E:251 ||| .
It  ||| S:251 E:254 ||| PRP
is  ||| S:254 E:257 ||| VBZ
an  ||| S:257 E:260 ||| DT
important  ||| S:260 E:270 ||| JJ
marker  ||| S:270 E:277 ||| NN
that  ||| S:277 E:282 ||| WDT
might  ||| S:282 E:288 ||| MD
not  ||| S:288 E:292 ||| RB
only  ||| S:292 E:297 ||| RB
indicate  ||| S:297 E:306 ||| VB
active  ||| S:306 E:313 ||| JJ
hepatitis  ||| S:313 E:323 ||| NNP
B  ||| S:323 E:325 ||| NNP
infection ||| S:325 E:334 ||| NN
,  ||| S:334 E:336 ||| ,
but  ||| S:336 E:340 ||| CC
may  ||| S:340 E:344 ||| MD
also  ||| S:344 E:349 ||| RB
predict  ||| S:349 E:357 ||| VB
clinical  ||| S:357 E:366 ||| JJ
and  ||| S:366 E:370 ||| CC
treatment  ||| S:370 E:380 ||| NN
outcomes ||| S:380 E:388 ||| NNS
.  ||| S:388 E:390 ||| .
Assays  ||| S:390 E:397 ||| NNP
for  ||| S:397 E:401 ||| IN
HBsAg  ||| S:401 E:407 ||| JJ
quantification  ||| S:407 E:422 ||| NNS
are  ||| S:422 E:426 ||| VBP
fully  ||| S:426 E:432 ||| RB
automated  ||| S:432 E:442 ||| VBN
with  ||| S:442 E:447 ||| IN
a  ||| S:447 E:449 ||| DT
high  ||| S:449 E:454 ||| JJ
output  ||| S:454 E:461 ||| NN
capacity ||| S:461 E:469 ||| NN
.  ||| S:469 E:471 ||| .
HBsAg  ||| S:471 E:477 ||| JJ
titer  ||| S:477 E:483 ||| NN
is  ||| S:483 E:486 ||| VBZ
higher  ||| S:486 E:493 ||| JJR
in  ||| S:493 E:496 ||| IN
HBe  ||| S:496 E:500 ||| JJ
antigen  ||| S:500 E:508 ||| NN
( ||| S:508 E:509 ||| -LRB-
HBeAg ||| S:509 E:514 ||| NNP
)  ||| S:514 E:516 ||| -RRB-
positive  ||| S:516 E:525 ||| JJ
chronic  ||| S:525 E:533 ||| JJ
hepatitis  ||| S:533 E:543 ||| NN
B  ||| S:543 E:545 ||| NN
than  ||| S:545 E:550 ||| IN
in  ||| S:550 E:553 ||| IN
HBeAg  ||| S:553 E:559 ||| JJ
negative  ||| S:559 E:568 ||| JJ
patients  ||| S:568 E:577 ||| NNS
and  ||| S:577 E:581 ||| CC
is  ||| S:581 E:584 ||| VBZ
negatively  ||| S:584 E:595 ||| RB
correlated  ||| S:595 E:606 ||| VBN
with  ||| S:606 E:611 ||| IN
liver  ||| S:611 E:617 ||| JJ
fibrosis  ||| S:617 E:626 ||| NN
in  ||| S:626 E:629 ||| IN
HBeAg  ||| S:629 E:635 ||| JJ
positive  ||| S:635 E:644 ||| JJ
patients ||| S:644 E:652 ||| NNS
.  ||| S:652 E:654 ||| .
In  ||| S:654 E:657 ||| IN
HBeAg  ||| S:657 E:663 ||| JJ
negative  ||| S:663 E:672 ||| JJ
chronic  ||| S:672 E:680 ||| JJ
hepatitis  ||| S:680 E:690 ||| NNP
B ||| S:690 E:691 ||| NNP
,  ||| S:691 E:693 ||| ,
an  ||| S:693 E:696 ||| DT
HBsAg  ||| S:696 E:702 ||| JJ
level  ||| S:702 E:708 ||| NN
< ||| S:708 E:710 ||| SYM
1,000  ||| S:710 E:716 ||| CD
IU ||| S:716 E:718 ||| NNP
/ ||| S:718 E:719 ||| NNP
mL  ||| S:719 E:722 ||| NNP
and  ||| S:722 E:726 ||| CC
an  ||| S:726 E:729 ||| DT
HBV  ||| S:729 E:733 ||| NNP
DNA  ||| S:733 E:737 ||| NNP
titer  ||| S:737 E:743 ||| VBD
< ||| S:743 E:745 ||| SYM
2,000  ||| S:745 E:751 ||| CD
IU ||| S:751 E:753 ||| NNP
/ ||| S:753 E:754 ||| NNP
mL  ||| S:754 E:757 ||| NNP
allow  ||| S:757 E:763 ||| VB
the  ||| S:763 E:767 ||| DT
accurate  ||| S:767 E:776 ||| JJ
identification  ||| S:776 E:791 ||| NN
of  ||| S:791 E:794 ||| IN
inactive  ||| S:794 E:803 ||| JJ
carriers ||| S:803 E:811 ||| NNS
.  ||| S:811 E:813 ||| .
On  ||| S:813 E:816 ||| IN
pegylated-interferon  ||| S:816 E:837 ||| NNP
( ||| S:837 E:838 ||| -LRB-
PEG-IFN ||| S:838 E:845 ||| NNP
)  ||| S:845 E:847 ||| -RRB-
treatment ||| S:847 E:856 ||| NN
,  ||| S:856 E:858 ||| ,
HBsAg  ||| S:858 E:864 ||| JJ
quantification  ||| S:864 E:879 ||| NN
allows  ||| S:879 E:886 ||| VBZ
identifying ||| S:886 E:897 ||| VBG
,  ||| S:897 E:899 ||| ,
as  ||| S:899 E:902 ||| IN
early  ||| S:902 E:908 ||| JJ
as  ||| S:908 E:911 ||| IN
week  ||| S:911 E:916 ||| NN
12  ||| S:916 E:919 ||| CD
PEG-IFN  ||| S:919 E:927 ||| JJ
therapy ||| S:927 E:934 ||| NN
,  ||| S:934 E:936 ||| ,
patients  ||| S:936 E:945 ||| NNS
that  ||| S:945 E:950 ||| WDT
will  ||| S:950 E:955 ||| MD
not  ||| S:955 E:959 ||| RB
benefit  ||| S:959 E:967 ||| VB
from  ||| S:967 E:972 ||| IN
therapy  ||| S:972 E:980 ||| NN
and  ||| S:980 E:984 ||| CC
thus  ||| S:984 E:989 ||| RB
stop  ||| S:989 E:994 ||| VB
or  ||| S:994 E:997 ||| CC
switch  ||| S:997 E:1004 ||| VB
treatment  ||| S:1004 E:1014 ||| NN
week  ||| S:1014 E:1019 ||| NN
12  ||| S:1019 E:1022 ||| CD
stopping  ||| S:1022 E:1031 ||| JJ
rule ||| S:1031 E:1035 ||| NN
.  ||| S:1035 E:1037 ||| .
Genotype  ||| S:1037 E:1046 ||| NNP
A  ||| S:1046 E:1048 ||| NNP
and  ||| S:1048 E:1052 ||| CC
D ||| S:1052 E:1053 ||| NNP
:  ||| S:1053 E:1055 ||| :
stop  ||| S:1055 E:1060 ||| VB
at  ||| S:1060 E:1063 ||| IN
week  ||| S:1063 E:1068 ||| NN
12  ||| S:1068 E:1071 ||| CD
if  ||| S:1071 E:1074 ||| IN
no  ||| S:1074 E:1077 ||| DT
HBsAg  ||| S:1077 E:1083 ||| JJ
decrease ||| S:1083 E:1091 ||| NN
;  ||| S:1091 E:1093 ||| :
Genotype  ||| S:1093 E:1102 ||| NNP
B  ||| S:1102 E:1104 ||| NNP
and  ||| S:1104 E:1108 ||| CC
C ||| S:1108 E:1109 ||| NNP
:  ||| S:1109 E:1111 ||| :
stop  ||| S:1111 E:1116 ||| VB
at  ||| S:1116 E:1119 ||| IN
week  ||| S:1119 E:1124 ||| NN
12  ||| S:1124 E:1127 ||| CD
if  ||| S:1127 E:1130 ||| IN
titer  ||| S:1130 E:1136 ||| CD
>  ||| S:1136 E:1138 ||| CD
20,000  ||| S:1138 E:1145 ||| CD
UI ||| S:1145 E:1147 ||| NNP
/ ||| S:1147 E:1148 ||| NNP
mL ||| S:1148 E:1150 ||| NNP
.  ||| S:1150 E:1152 ||| .
With  ||| S:1152 E:1157 ||| IN
regards  ||| S:1157 E:1165 ||| VBG
to  ||| S:1165 E:1168 ||| TO
nucleos ||| S:1168 E:1175 ||| VB
[ ||| S:1175 E:1176 ||| -LRB-
t ||| S:1176 E:1177 ||| LS
] ||| S:1177 E:1178 ||| -RRB-
ides  ||| S:1178 E:1183 ||| JJ
analogues  ||| S:1183 E:1193 ||| JJ
therapy  ||| S:1193 E:1201 ||| NN
the  ||| S:1201 E:1205 ||| DT
role  ||| S:1205 E:1210 ||| NN
of  ||| S:1210 E:1213 ||| IN
HBsAg  ||| S:1213 E:1219 ||| JJ
quantification  ||| S:1219 E:1234 ||| NN
remains  ||| S:1234 E:1242 ||| VBZ
to  ||| S:1242 E:1245 ||| TO
be  ||| S:1245 E:1248 ||| VB
clarified ||| S:1248 E:1257 ||| VBN
.  ||| S:1257 E:1259 ||| .
Several  ||| S:1259 E:1267 ||| JJ
studies  ||| S:1267 E:1275 ||| NNS
indicate  ||| S:1275 E:1284 ||| VBP
that  ||| S:1284 E:1289 ||| DT
baseline  ||| S:1289 E:1298 ||| NN
and  ||| S:1298 E:1302 ||| CC
on-treatment  ||| S:1302 E:1315 ||| JJ
HBsAg  ||| S:1315 E:1321 ||| JJ
levels  ||| S:1321 E:1328 ||| NNS
might  ||| S:1328 E:1334 ||| MD
allow  ||| S:1334 E:1340 ||| VB
identifying  ||| S:1340 E:1352 ||| VBG
patients  ||| S:1352 E:1361 ||| NNS
that  ||| S:1361 E:1366 ||| WDT
can  ||| S:1366 E:1370 ||| MD
end  ||| S:1370 E:1374 ||| VB
up  ||| S:1374 E:1377 ||| RP
with  ||| S:1377 E:1382 ||| IN
treatment  ||| S:1382 E:1392 ||| NN
with  ||| S:1392 E:1397 ||| IN
no  ||| S:1397 E:1400 ||| DT
subsequent  ||| S:1400 E:1411 ||| JJ
risk  ||| S:1411 E:1416 ||| NN
of  ||| S:1416 E:1419 ||| IN
reactivation ||| S:1419 E:1431 ||| NN
.  ||| S:1431 E:1433 ||| .
In  ||| S:1433 E:1436 ||| IN
clinical  ||| S:1436 E:1445 ||| JJ
practice ||| S:1445 E:1453 ||| NN
,  ||| S:1453 E:1455 ||| ,
HBsAg  ||| S:1455 E:1461 ||| JJ
quantification  ||| S:1461 E:1476 ||| NN
is  ||| S:1476 E:1479 ||| VBZ
a  ||| S:1479 E:1481 ||| DT
simple  ||| S:1481 E:1488 ||| JJ
and  ||| S:1488 E:1492 ||| CC
reproducible  ||| S:1492 E:1505 ||| JJ
worthwhile  ||| S:1505 E:1516 ||| JJ
tool  ||| S:1516 E:1521 ||| NN
that  ||| S:1521 E:1526 ||| WDT
can  ||| S:1526 E:1530 ||| MD
be  ||| S:1530 E:1533 ||| VB
used  ||| S:1533 E:1538 ||| VBN
in  ||| S:1538 E:1541 ||| IN
association  ||| S:1541 E:1553 ||| NN
with  ||| S:1553 E:1558 ||| IN
HBV  ||| S:1558 E:1562 ||| NNP
DNA  ||| S:1562 E:1566 ||| NNP
to  ||| S:1566 E:1569 ||| TO
classify  ||| S:1569 E:1578 ||| VB
patients  ||| S:1578 E:1587 ||| NNS
during  ||| S:1587 E:1594 ||| IN
HBV  ||| S:1594 E:1598 ||| NNP
infection  ||| S:1598 E:1608 ||| NN
and  ||| S:1608 E:1612 ||| CC
to  ||| S:1612 E:1615 ||| TO
monitor  ||| S:1615 E:1623 ||| VB
therapy ||| S:1623 E:1630 ||| NN
.  ||| S:1630 E:1632 ||| .
